BRPI0513419A - transgene de distrofina retinal e métodos de uso do mesmo - Google Patents

transgene de distrofina retinal e métodos de uso do mesmo

Info

Publication number
BRPI0513419A
BRPI0513419A BRPI0513419-6A BRPI0513419A BRPI0513419A BR PI0513419 A BRPI0513419 A BR PI0513419A BR PI0513419 A BRPI0513419 A BR PI0513419A BR PI0513419 A BRPI0513419 A BR PI0513419A
Authority
BR
Brazil
Prior art keywords
mice
transgenic
dystrophin
severe
transgene
Prior art date
Application number
BRPI0513419-6A
Other languages
English (en)
Inventor
Robert White
Roger Gaedigk
Kathleen Fitzgerald-Gustafson
Original Assignee
Childrens Mercy Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Mercy Hospital filed Critical Childrens Mercy Hospital
Publication of BRPI0513419A publication Critical patent/BRPI0513419A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

TRANSGENE DE DISTROFINA RETINAL E MéTODOS DE USO DO MESMO. A presente invenção refere-se a Distrofia Muscular de Duchenne (DMD) que é uma doença muscular progressiva que é causada por defeitos graves no gene de distrofina e resulta em morte do paciente em torno da terceira idade. A presente invenção utiliza o camundongo Mutante Duplo (DM) como um modelo humano apropriado para DMD, uma vez que esses camundongos são deficientes de distrofina e utrofina (mdxl+, utrn -/-), morrem em 3 meses de idade e sofrem de fraqueza muscular grave, retardo pronunciado do crescimento, cifose, perda de peso, postura relapsa e imobilidade. Foi mostrado que a expressão, a partir de um transgene, da nova distrofina retinal humana Dp260previne a morte prematura e reduz o fenótipo de distrofia muscular grave para miopatia clínica branda. Eletromiografia, histologia, radiografia, formação de imagem por ressonância magnética e estudos de comportamento concluíram que camundongos transgênicos DM cresceram normalmente, tiveram a curvatura espinhal e mobilidade normal e tiveram a patologia muscular diminuída. EMG e dados histológicos de camundongos DM transgênicos mostraram anormalidades diminuídas para níveis típicos de miopatia branda, enquanto que camundongos DM exibiram anormalidades graves comumente observadas em distrofinopatias humanas. Os camundongos DM transgênicos também tinham níveis de movimento mensuráveis comparado com aqueles de camundongos mdx não tratados e controles.
BRPI0513419-6A 2004-07-16 2005-07-15 transgene de distrofina retinal e métodos de uso do mesmo BRPI0513419A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58870004P 2004-07-16 2004-07-16
US60825204P 2004-09-09 2004-09-09
US61302604P 2004-09-24 2004-09-24
US11/050,911 US20080044393A1 (en) 2004-07-16 2005-02-04 Retinal dystrophin transgene and methods of use thereof
PCT/US2005/025375 WO2006020184A2 (en) 2004-07-16 2005-07-15 Retinal dystrophin transgene and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0513419A true BRPI0513419A (pt) 2008-05-06

Family

ID=35907962

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513419-6A BRPI0513419A (pt) 2004-07-16 2005-07-15 transgene de distrofina retinal e métodos de uso do mesmo

Country Status (11)

Country Link
US (1) US20080044393A1 (pt)
EP (1) EP1781792A4 (pt)
JP (1) JP2008506394A (pt)
KR (1) KR20070059058A (pt)
AU (1) AU2005274798B2 (pt)
BR (1) BRPI0513419A (pt)
CA (1) CA2574098A1 (pt)
IL (1) IL180734A0 (pt)
MX (1) MX2007000633A (pt)
NZ (1) NZ553137A (pt)
WO (1) WO2006020184A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120142609A1 (en) * 2009-06-26 2012-06-07 Abdoulaye Sene Non human animal models for increased retinal vascular permeability
JP6832280B2 (ja) 2015-01-16 2021-02-24 ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ 新規のマイクロジストロフィンおよび使用の関連する方法
MA45477A (fr) 2016-04-15 2019-02-20 Res Inst Nationwide Childrens Hospital Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
US11202840B2 (en) 2016-06-21 2021-12-21 The Curators Of The University Of Missouri Modified dystrophin proteins
EP3596112A2 (en) 2017-03-17 2020-01-22 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
US20200199621A1 (en) * 2017-03-17 2020-06-25 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
EP3697915A4 (en) 2017-10-18 2021-12-08 Research Institute at Nationwide Children's Hospital ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE SPECIFIC MICRODYSTROPHIN FOR THE TREATMENT OF MUSCLE DYSTROPHY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239060A (en) * 1986-07-25 1993-08-24 The Children's Medical Center Corporation Muscular dystrophy protein, dystrophin
US5541074A (en) * 1986-07-25 1996-07-30 The Children's Medical Center Corporation Antibodies to dystrophin and uses therefor
ES2140359T1 (es) * 1993-06-14 2000-03-01 Basf Ag Control preciso de expresion genetica en celulas eucarioticas mediante promotores que responden a la tetaciclina.
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6171855B1 (en) * 1998-05-28 2001-01-09 The Regents Of The University Of Michigan Vectors
AU764686B2 (en) * 1998-08-28 2003-08-28 Duke University Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences
EP2017338A1 (en) * 2001-05-24 2009-01-21 Genzyme Corporation Muscle-specific expression vectors
WO2003016495A2 (en) * 2001-08-20 2003-02-27 Merck & Co., Inc. Transgenic rodents as animal models for modulation of b1 bradykinin receptor protein
AU2003242380A1 (en) * 2002-06-17 2003-12-31 Nagoya Industrial Science Research Institute Method of slective isolation or visualization of target cells differentiated from embryonic stem cells or kit for visualization

Also Published As

Publication number Publication date
CA2574098A1 (en) 2006-02-23
JP2008506394A (ja) 2008-03-06
AU2005274798B2 (en) 2011-11-17
US20080044393A1 (en) 2008-02-21
WO2006020184A3 (en) 2006-09-14
AU2005274798A1 (en) 2006-02-23
EP1781792A2 (en) 2007-05-09
WO2006020184A2 (en) 2006-02-23
IL180734A0 (en) 2007-06-03
MX2007000633A (es) 2008-03-04
NZ553137A (en) 2009-11-27
KR20070059058A (ko) 2007-06-11
EP1781792A4 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
Eckert Phenotypic approaches to obstructive sleep apnoea–new pathways for targeted therapy
BRPI0513419A (pt) transgene de distrofina retinal e métodos de uso do mesmo
Matsuo et al. Kinematic linkage of the tongue, jaw, and hyoid during eating and speech
Isono Obesity and obstructive sleep apnoea: mechanisms for increased collapsibility of the passive pharyngeal airway
Vroegop et al. Effects of vertical opening on pharyngeal dimensions in patients with obstructive sleep apnoea
Vialle et al. Neuromuscular scoliosis
Tsuiki et al. Oropharyngeal crowding and obesity as predictors of oral appliance treatment response to moderate obstructive sleep apnea
Messina et al. Infantile spinal muscular atrophy with respiratory distress type I (SMARD 1): an atypical phenotype and review of the literature
Takaso et al. Surgical correction of spinal deformity in patients with congenital muscular dystrophy
Frerichs et al. Regional respiratory inflation and deflation pressure–volume curves determined by electrical impedance tomography
Dipti et al. Brown–Vialetto–Van Laere syndrome; variability in age at onset and disease progression highlighting the phenotypic overlap with Fazio-Londe disease
Cavalheri et al. Effects of arm bracing posture on respiratory muscle strength and pulmonary function in patients with chronic obstructive pulmonary disease
CN201211301Y (zh) 牵引床
Stankiewicz-Rudnicki et al. Assessment of regional ventilation in acute respiratory distress syndrome by electrical impedance tomography
Mercuri et al. Clinical studies of RG7916 in patients with spinal muscular atrophy: SUNFISH part 1 study update
O’Halloran et al. Breathing with neuromuscular disease: Does compensatory plasticity in the motor drive to breathe offer a potential therapeutic target in muscular dystrophy?
Montes et al. SMA–THERAPY: P. 269 impact of continued nusinersin treatment on caregiver experience and health-related quality of life in later-onset SMA: results from the SHINE study
Himanen et al. Prolonged partial obstruction during sleep is a NREM phenomenon
Shao Growth & Development
So et al. Reduction in myoclonus and ataxia following the use of perampanel in patient with sialidosis type 1
Shi et al. Upper airway morphology in adults with positional obstructive sleep apnea
Choudhury et al. Neuromuscular scoliosis: clinical presentation, types of deformity, assessment and principles of treatment
Munell et al. CONGENITAL MUSCULAR DYSTROPHIES: P. 325Severe loss of semimembranosus muscle bulk is an early phenomenon in SEPN1-related muscle disorders: toward early recognition of early-onset muscle disorders by imaging
Long et al. SMA–THERAPY: P. 270 Myostatin dynamics in health and disease: Pharmacologic effects of SRK-015, a highly selective monoclonal antibody inhibitor of myostatin activation
Shichiji et al. CONGENITAL MUSCULAR DYSTROPHIES: P. 323Review of the natural history of mental development in Fukuyama congenital muscular dystrophy patients, based on a written questionnaire from their families

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.